美国 · SEC FORM 4
Compass Therapeutics, Inc.
CMPX · Nasdaq · CIK 0001738021 · Healthcare · Biotechnology
内部人信号
2 位买方 · 4 条买入交易行 · $96.8K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ✓ 角色得分高 · 买入者中职位最高的是：Chief Accounting Officer
- ✓ Recent activity · latest purchase 2026-10-01
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
买方广度与集中度
Roles in the peak window: Chief Accounting Officer, General Counsel. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
最新留档分数
- 57.4
- 57.3
- 57.2
- 56.9
- 56.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -51.6%
- 3M
- -56.1%
- 6M
- -80.8%
- 12M
- -74.5%
波动率与流动性
- 波动率
- 95.5%
- Beta
- —
- 平均每日成交额
- USD 4.2M
估值
- 市值
- USD 178.8M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -33.8%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-28 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 40,357,710
- 上期报告
- 41,647,512
- 日均成交量
- 6,449,901
- 回补天数
- 6.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Lerner Neil | 买入 (P) | Common Stock | 20,000 | USD 0.92 | USD 18,400 | SEC 申报 ↗ |
| 2026-09-24 | Lerner Neil | 买入 (P) | Common Stock | 2,500 | USD 1.14 | USD 2,850 | SEC 申报 ↗ |
| 2026-04-29 | Lerner Neil | 买入 (P) | Common Stock | 15,000 | USD 1.89 | USD 28,350 | SEC 申报 ↗ |
| 2026-04-29 | Anderman Jonathan | 买入 (P) | Common Stock | 25,000 | USD 1.89 | USD 47,250 | SEC 申报 ↗ |
| 2025-05-27 | Schuetz Thomas J. | 买入 (P) | Common Stock | 10,000 | USD 2.11 | USD 21,100 | SEC 申报 ↗ |
| 2025-04-07 | Lerner Neil | 买入 (P) | Common Stock | 20,000 | USD 1.42 | USD 28,400 | SEC 申报 ↗ |
| 2025-04-07 | Anderman Jonathan | 买入 (P) | Common Stock | 20,000 | USD 1.54 | USD 30,800 | SEC 申报 ↗ |
| 2023-03-10 | Schuetz Thomas J. | 买入 (P) | Common Stock | 10,000 | USD 3.37 | USD 33,700 | SEC 申报 ↗ |
| 2023-02-27 | Schuetz Thomas J. | 买入 (P) | Common Stock | 20,000 | USD 3.98 | USD 79,600 | SEC 申报 ↗ |
| 2023-02-15 | Schuetz Thomas J. | 买入 (P) | Common Stock | 20,000 | USD 3.86 | USD 77,200 | SEC 申报 ↗ |
| 2023-01-31 | Schuetz Thomas J. | 买入 (P) | Common Stock | 20,000 | USD 4.05 | USD 81,000 | SEC 申报 ↗ |
| 2023-01-24 | Schuetz Thomas J. | 买入 (P) | Common Stock | 20,000 | USD 4.19 | USD 83,800 | SEC 申报 ↗ |
| 2022-11-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP V LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 402,000 | USD 3.21 | USD 1,290,420 | SEC 申报 ↗ |
| 2022-11-08 | GORDON CARL L | 买入 (P) | Common Stock | 402,000 | USD 3.21 | USD 1,290,420 | SEC 申报 ↗ |
| 2022-09-28 | Schuetz Thomas J. | 买入 (P) | Common Stock | 10,000 | USD 2.32 | USD 23,200 | SEC 申报 ↗ |
Form 4 申报证据
13 transaction lines in the latest 365-day window; 82 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Lerner Neil | 买入 (P) | Common Stock | 20,000 | USD 0.92 | USD 18,400 | SEC 申报 ↗ |
| 2026-09-24 | Lerner Neil | 买入 (P) | Common Stock | 2,500 | USD 1.14 | USD 2,850 | SEC 申报 ↗ |
| 2026-04-29 | Lerner Neil | 买入 (P) | Common Stock | 15,000 | USD 1.89 | USD 28,350 | SEC 申报 ↗ |
展开近期 Form 4 证据 (13 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Lerner Neil | 买入 (P) | Common Stock | 20,000 | USD 0.92 | USD 18,400 | SEC 申报 ↗ |
| 2026-09-24 | Lerner Neil | 买入 (P) | Common Stock | 2,500 | USD 1.14 | USD 2,850 | SEC 申报 ↗ |
| 2026-04-29 | Lerner Neil | 买入 (P) | Common Stock | 15,000 | USD 1.89 | USD 28,350 | SEC 申报 ↗ |
| 2026-04-29 | Anderman Jonathan | 买入 (P) | Common Stock | 25,000 | USD 1.89 | USD 47,250 | SEC 申报 ↗ |
| 2026-04-29 | Lerner Neil | 奖励／授予 (A) | Common Stock | 15,000 | USD 1.89 | USD 28,350 | SEC 申报 ↗ |
| 2026-04-29 | Anderman Jonathan | 奖励／授予 (A) | Common Stock | 25,000 | USD 1.89 | USD 47,250 | SEC 申报 ↗ |
| 2026-02-08 | Schuetz Thomas J. | 代扣税 (F) | Common Stock | 36,687 | USD 6.52 | USD 239,199 | SEC 申报 ↗ |
| 2026-01-09 | Schuetz Thomas J. | 代扣税 (F) | Common Stock | 46,777 | USD 5.35 | USD 250,257 | SEC 申报 ↗ |
| 2026-01-02 | Shin Barry | 奖励／授予 (A) | Common Stock | 125,000 | USD 5.17 | USD 646,250 | SEC 申报 ↗ |
| 2026-01-02 | Schuetz Thomas J. | 奖励／授予 (A) | Common Stock | 250,000 | USD 5.17 | USD 1,292,500 | SEC 申报 ↗ |
| 2026-01-02 | Lerner Neil | 奖励／授予 (A) | Common Stock | 62,500 | USD 5.17 | USD 323,125 | SEC 申报 ↗ |
| 2026-01-02 | Anderman Jonathan | 奖励／授予 (A) | Common Stock | 150,000 | USD 5.17 | USD 775,500 | SEC 申报 ↗ |
| 2025-11-16 | Schuetz Thomas J. | 代扣税 (F) | Common Stock | 44,025 | USD 4.83 | USD 212,641 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CMPX |
| CIK | 0001738021 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 82 transaction lines from 2020-06-19 to 2026-10-01 52 P purchase lines · 7 S sale lines · 23 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.